Promore Pharma AB (publ) Year-end report 2018
October to December · Net sales amounted to 1.4 (0.6) MSEK. · The operating loss for the period was 6.5 (-10.4) MSEK · Net loss was 7.2 (-10.9) MSEK, corresponding to a loss per share of SEK 0.35 (-0.54) · Cash flow from operating activities amounted to -8.7 (0.2) MSEK · Cash and cash equivalents amounted to 30.9 (63.0) MSEK January to December · Net sales amounted to 2.4 (0.6) MSEK. · The operating loss for the period was 32.7 MSEK (-9.6) MSEK · Net loss was 32.5 (-8.4) MSEK, corresponding to a loss per share of SEK -1.61 (-0.51) · Cash flow from operating